Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 5/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 8/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15628618 | 1.00 | WDR91 (0.40) | WDR91RORCARPHGDHLOXL2 | |
| SCHEMBL15628606 | 0.88 | DPP4 (0.35) | ACACB | |
| SCHEMBL15628549 | 0.88 | DPP4 (0.35) | ACACB | |
| SCHEMBL15628607 | 0.80 | ALDH1A1 (0.38) | — | |
| SCHEMBL13527745 | 0.80 | WDR91 (0.36) | WDR91RORCARPHGDHACACB | |
| SCHEMBL20026296 | 0.80 | WDR91 (0.36) | WDR91RORCARPHGDHACACB | |
| SCHEMBL13527743 | 0.80 | WDR91 (0.36) | WDR91RORCARPHGDHACACB | |
| SCHEMBL15628457 | 0.79 | ALDH1A1 (0.40) | — | |
| SCHEMBL20026360 | 0.79 | ACACB (0.30) | ACACB | |
| SCHEMBL19062581 | 0.78 | ALDH1A1 (0.41) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | WDR91 1756/4885RORC 316/4885AR 4501/4885 |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | WDR91 1756/4885RORC 316/4885AR 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.